They are biologically and therapeutically interesting peptides, not only because of their potential anti-hyperglycaemic effects in Type 2 diabetes, but also because GLP-1 reduces appetite and GIP modulates how the body handles dietary fats. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.